Andrew P South 1 , * , Karin J Purdie 2 , Stephen A Watt 1 , Sam Haldenby 3 , Nicoline den Breems 1 , Michelle Dimon 4 , Sarah T Arron 4 , Michael J Kluk 5 , Jon C Aster 5 , Angela McHugh 1 , Dylan J Xue 1 , Jasbani HS Dayal 1 , Kim S Robinson 1 , SM Hasan Rizvi 6 , Charlotte M Proby 1 , Catherine A Harwood 2 , Irene M Leigh 1 , 2
24 March 2014
Cutaneous SCC (cSCC) is the most frequent skin cancer with metastatic potential and can manifest rapidly as a common side effect in patients receiving systemic kinase inhibitors. Here we use massively parallel exome and targeted level sequencing 132 sporadic cSCC, 39 squamoproliferative lesions and cSCC arising in patients receiving the BRAF inhibitor vemurafenib, as well as 10 normal skin samples to identify significant NOTCH1 mutation as an early event in squamous cell carcinogenesis. Bisected vemurafenib induced lesions revealed surprising heterogeneity with different activating HRAS and NOTCH1 mutations identified in two halves of the same cSCC suggesting polyclonal origin.
Immunohistochemical analysis using an antibody specific to nuclear NOTCH1 correlates with mutation status in sporadic cSCC and regions of NOTCH1 loss or down-regulation are frequently observed in normal looking skin. Our data indicate that NOTCH1 acts as a gatekeeper in human cSCC.